Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND METHODS: To examine the clinical course of human immunodeficiency virus (HIV) infection in injection-drug users, we conducted a prospective study of a cohort of patients in a methadone-treatment program in New York City from July 1985 through December 1990. The patients underwent standardized evaluations at base line and semiannually thereafter and received on-site primary medical care. Rates of progression to the acquired immunodeficiency syndrome (AIDS) and major outcomes before the development of AIDS were examined by univariate analyses; the risk of AIDS was also assessed by product-limit survival analysis and proportional-hazards regression. RESULTS: Of 318 HIV-seropositive patients who did not yet have AIDS (171 men and 147 women), 90 were black, 179 were Hispanic, and 49 were white; the median age was 33 years. Over a median of 3.0 years of follow-up, 55 (17 percent) received a diagnosis of AIDS (incidence per 100 person-years, 5.8). Major outcomes before the development of AIDS included oral candidiasis (incidence per 100 person-years, 11.2), pyogenic bacterial infections including pneumonia and sepsis (8.0), pulmonary tuberculosis (1.2), multiple constitutional symptoms (13.6), and herpes zoster (1.3). There were 41 deaths from AIDS, and 13 seropositive patients without AIDS (4.1 percent) died of bacterial infections, as compared with only 1 of 411 seronegative patients studied (P < 0.001). The incidence of AIDS was 62 percent lower among those who took zidovudine than among those who did not (P = 0.02). In the multivariate analysis, progression to AIDS was best predicted by low numbers and percentages of CD4+ lymphocytes, nonuse of zidovudine, and the presence of oral candidiasis, bacterial infections, or tuberculosis. There was no consistent relation between progression to disease and the continued use of injection drugs. CONCLUSIONS: HIV-infected injection-drug users have progression to AIDS at rates comparable to those of other HIV-infected groups, but they have substantial pre-AIDS morbidity and mortality, particularly from bacterial infections, which also appear to predict disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HIV-positive individuals may have a heightened susceptibility to bacterial infections [11,12]”
From Prevalence and correlates of abscesses among a cohort of injection drug users (2005) · cites this paper as [11]
In the citing paper
“the association between HIV-positive status and having an abscess has been noted elsewhere”
From Prevalence and correlates of abscesses among a cohort of injection drug users (2005) · cites this paper as [11]
In the citing paper
“high risk of infectious complications, such as endocarditis from abscesses [10], occur among HIV infected individuals [11]”
From Prevalence and correlates of abscesses among a cohort of injection drug users (2005) · cites this paper as [11]
Citations
Cites
Lane, H. C., Masur, H., Edgar, L. C., Whalen, G., Rook, A. H., & Fauci, A. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308253090803 · Cited by 1,600
Selwyn, P. A., Hartel, D., Lewis, V. A., Schoenbaum, E. E., Vermund, S. H., Klein, R. S., Walker, A. T., & Friedland, G. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200901 · Cited by 1,574
Self-citationVolberding, P. A., Lagakos, S. W., Koch, M. A., Pettinelli, C., Myers, M. W., Booth, D. K., Balfour, H. H., Reichman, R. C., Bartlett, J. A., Hirsch, M. S., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004053221401 · Cited by 1,283
Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?
Beral, V., Peterman, T. A., Berkelman, R. L., & Jaffe, H. W. (1990) · The Lancet · doi:10.1016/0140-6736(90)90001-l · Cited by 1,056
Fahey, J. L., Taylor, J. M. G., Detels, R., Hofmann, B., Melmed, R., Nishanian, P., & Giorgi, J. V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001183220305 · Cited by 1,023
Klein, R. S., Harris, C. A., Small, C. B., Moll, B., Lesser, M., & Friedland, G. H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408093110602 · Cited by 863
Self-citationPhair, J., Muñoz, A., Detels, R., Kaslow, R., Rinaldo, C., Saah, A., & the Multicenter AIDS Cohort Study Group* (1990) · New England Journal of Medicine · doi:10.1056/nejm199001183220304 · Cited by 684
Fischl, M. A., Richman, D. D., Hansen, N., Collier, A. C., Carey, J. T., Para, M. F., Hardy, W. D., Dolin, R., Powderly, W. G., Allan, J. D., et al. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-10-727 · Cited by 601
Moss, A. R., Bacchetti, P., Osmond, D., Krampf, W., Chaisson, R. E., Stites, D., Wilber, J., Allain, J.-P., & Carlson, J. (1988) · BMJ · doi:10.1136/bmj.296.6624.745 · Cited by 544
Goedert, J. J., Kessler, C. M., Aledort, L. M., Biggar, R. J., Andes, W. A., White, G. C., Drummond, J. E., Vaidya, K., Mann, D. L., Eyster, M. E., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198910263211701 · Cited by 524
Research works printed but not linked: 15
- 1989, MMWR Morb Mortal Wkly Rep, 38, 165
- 1991, Wkly Epidemiol Rec, 66, 33
- Muñoz, 1992, J Acquir Immune Defic Syndr, 5, 694
- Des Jarlais, 1987, AIDS, 1, 105
- Casabona, 1990, J Acquir Immune Defic Syndr, 3, 272
- 1989, MMWR Morb Mortal Wkly Rep, 38, 1
- Gates JR, Collado E, Budner NS, Schoenbaum EE. Retaining participation in a prospective study of HIV among intravenous drug users (IVDUs) in New York City. In: Abstracts of the Seventh International Conference on AIDS, Florence, Italy, June 16–21, 1991. Vol. 2. Rome: Istituto Superiore di Sanità, 1991:377.
- 1986, MMWR Morb Mortal Wkly Rep, 35, 334
- 1987, MMWR Morb Mortal Wkly Rep, 36, 1S
- 1991, MMWR Morb Mortal Wkly Rep, 40, 891
- 1990, Wkly Epidemiol Rec, 65, 221
- 1991, MMWR Morb Mortal Wkly Rep, 40, 1
- Selik, 1990, J Acquir Immune Defic Syndr, 3, 73
- Ragni, 1990, J Acquir Immune Defic Syndr, 3, 708
- Rosenberg, 1991, J Acquir Immune Defic Syndr, 4, 392
Cited by
Deacon, N. J., Tsykin, A., Solomon, A., Smith, K., Ludford-Menting, M., Hooker, D. J., McPhee, D. A., Greenway, A. L., Ellett, A., Chatfield, C., et al. (1995) · Science · doi:10.1126/science.270.5238.988 · Cited by 1,155
Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C., Buono, D., Eckholdt, H., Howard, A. A., & Schoenbaum, E. E. (2001) · Clinical Infectious Diseases · doi:10.1086/323201 · Cited by 637
“Subjects were recruited from the Bronx HIV Epidemiologic Research on Outcomes Study (HEROS), an ongoing cohort of drug users at Montefiore Medical Center, Bronx, New York, that began in 1985 [25, 26].”
MethodSelf-citationBacterial Pneumonia in Persons Infected with the Human Immunodeficiency Virus
Hirschtick, R. E., Glassroth, J., Jordan, M. C., Wilcosky, T. C., Wallace, J. M., Kvale, P. A., Markowitz, N., Rosen, M. J., Mangura, B. T., & Hopewell, P. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331305 · Cited by 615
Caws, M., Thwaites, G., Dunstan, S., Hawn, T. R., Thi Ngoc Lan, N., Thuong, N. T. T., Stepniewska, K., Huyen, M. N. T., Bang, N. D., Huu Loc, T., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000034 · Cited by 498
“infection converting to active disease from 1 in 10 to 1 in 3 [1]”
BackgroundUnderstanding Latent Tuberculosis: A Moving Target
Lin, P. L., & Flynn, J. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903856 · Cited by 488
“Impaired immunity, as in the case of HIV infection, increases the risk to 10% per year (8).”
Background
Metadata
- Authors
- Selwyn, P. A., Alcabes, P., Hartel, D., Buono, D., Schoenbaum, E. E., Klein, R. S., Davenny, K., & Friedland, G. H.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1992-12-10
- Volume
- 327
- Issue
- 24
- Pages
- 1697-1703
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2337820820
- Cited by
- 282
- References
- 54
- Citations by year
- 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 7 · 2015: 3 · 2014: 5 · 2013: 4 · 2012: 7
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01da004347-15)
- U.S. Public Health Service (U64CCU200714)
- National Institute on Drug Abuse (DAO4347-05)
- Topics
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- HIV infection, people who inject drugs, AIDS progression, methadone maintenance treatment, zidovudine, CD4 count, oral candidiasis, bacterial infection, tuberculosis, AIDS mortality, risk factors for progression
- MeSH terms
- Acquired Immunodeficiency Syndrome, Adult, Bacterial Infections, Candidiasis, Oral, Female, Follow-Up Studies, Humans, Leukocyte Count, Male, New York City, Prospective Studies, Zidovudine, CD4-Positive T-Lymphocytes, HIV Infections, Substance Abuse, Intravenous, Multivariate Analysis, Proportional Hazards Models, AIDS-Related Opportunistic Infections, Racial Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. https://app.cochat.ai/papers/10.1056/nejm199212103272401
- The paper
- Selwyn, P. A., Alcabes, P., Hartel, D., Buono, D., Schoenbaum, E. E., Klein, R. S., Davenny, K., & Friedland, G. H. (1992). Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. New England Journal of Medicine. https://doi.org/10.1056/nejm199212103272401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.